Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer.

about

Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer.

Item

http://www.wikidata.org/entity/Q49710712

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer.

@en

Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer.

@nl

type

Item

label

Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer.

@en

Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer.

@nl

prefLabel

Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer.

@en

Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer.

@nl

P1476

Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer

@en

P2093

Hidejiro Torigoe

http://www.w3.org/2001/XMLSchema#string

Hiroaki Asano

http://www.w3.org/2001/XMLSchema#string

Hiroki Sato

http://www.w3.org/2001/XMLSchema#string

Kazunori Tsukuda

http://www.w3.org/2001/XMLSchema#string

Kei Namba

http://www.w3.org/2001/XMLSchema#string

Shuta Tomida

http://www.w3.org/2001/XMLSchema#string

Toshiyoshi Fujiwara

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Activating HER2 mutations in HER2 gene amplification negative breast cancer

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Global cancer statistics, 2012

Comprehensive molecular characterization of gastric adenocarcinoma

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data

The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes

Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal

Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells.

P304

1166-1176

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CAS.13546

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-03-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29465762

http://www.w3.org/2001/XMLSchema#string

P932

5891184

http://www.w3.org/2001/XMLSchema#string